In the melanoma cohort 15 patients had received both an anti-CTLA4 and an anti-PD-1/PD-L1, 16 patients had received an anti-PD-1/PD-L1, and 5 patients had received an anti-CTLA4. The gene discussed is PDCD1; the disease is melanoma.